Wall Street Zen upgraded shares of Evaxion A/S (NASDAQ:EVAX – Free Report) to a hold rating in a report published on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Tuesday, October 6th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.25.
View Our Latest Stock Report on EVAX
Evaxion A/S Price Performance
EVAX stock opened at $2.77 on Friday. Evaxion A/S has a 52 week low of $2.65 and a 52 week high of $6.92. The firm has a market capitalization of $24.99 million, a P/E ratio of -2.29 and a beta of 0.60. The company has a fifty day simple moving average of $3.12 and a two-hundred day simple moving average of $3.42. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69.
Hedge Funds Weigh In On Evaxion A/S
Several large investors have recently modified their holdings of the stock. Rathbones Group PLC purchased a new stake in Evaxion A/S during the 1st quarter valued at $170,000. Renaissance Technologies LLC purchased a new position in Evaxion A/S during the first quarter worth $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in Evaxion A/S during the first quarter worth $112,000. Institutional investors own 11.04% of the company’s stock.
About Evaxion A/S
Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.
See Also
- Five stocks we like better than Evaxion A/S
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.
